Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Can-Fite is a clinical-stage biopharmaceutical company developing orally bioavailable small molecule therapeutics targeting the A3 adenosine receptor (A3AR). The company's pipeline includes Piclidenoson (CF101) for psoriasis and Lowe Syndrome, Namodenoson (CF102) for hepatocellular carcinoma (HCC), MASH, and pancreatic cancer, and CF602 for erectile dysfunction. The company has no commercial product sales and relies on out-licensing agreements and equity financing.
Key Financial Metrics
| Metric (USD in thousands) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenues | $674 | $743 | $810 |
| Research & Development Expenses | $(5,757) | $(5,983) | $(7,763) |
| General & Administrative Expenses | $(3,047) | $(2,955) | $(3,143) |
| Net Loss | $(7,880) | $(7,634) | $(10,173) |
| Cash and Cash Equivalents (Year End) | $4,825 | $4,278 | $2,978 |
| Short-Term Deposits (Year End) | $3,057 | $4,625 | $N/A |
| Accumulated Deficit | $(166,361) | $(158,481) | $(150,847) |
| Shareholders' Equity | $5,436 | $6,243 | $4,472 |
Note: The filing text does not provide a specific "Operating Cash Flow" line item in the summary tables, but the Consolidated Statements of Cash Flows indicate Net Cash Used in Operating Activities was $(7,637) for 2024.
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased by 9.3% to $0.67 million in 2024 from $0.74 million in 2023. This was primarily due to lower recognition of advance payments from Ewopharma, Gebro, CKD, and Cipher, partially offset by revenue recognition from the Vetbiolix agreement.
- Expense Reduction: R&D expenses decreased by 3.8% to $5.75 million, driven by reduced costs associated with the Piclidenoson program. G&A expenses increased slightly by 3.1% to $3.04 million due to higher public relations costs.
- Capital Raising: In August 2024, the company raised approximately $5.0 million in gross proceeds via a warrant inducement transaction. Additionally, an At-The-Market (ATM) offering agreement was executed, generating approximately $2.4 million in gross proceeds by year-end.
- Share Count: Ordinary shares outstanding increased significantly from 1.36 billion in 2023 to 2.98 billion in 2024 due to warrant exercises and ATM sales.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management projects that existing financial resources (approximately $7.9 million in cash and short-term deposits as of Dec 31, 2024) will be sufficient to meet requirements for at least twelve months from the filing date. A contingency plan involving cost reductions, deferral of R&D programs, and reduction in management compensation is in place if additional financing is not secured.
Key Risks and Contingencies:
- Going Concern: The company has a history of losses and negative operating cash flows. Continued operations depend on raising additional capital, which may not be available on acceptable terms.
- Listing Status: The company is not currently in compliance with NYSE American continued listing standards regarding shareholders' equity (requires $6 million if reporting losses). Failure to comply could result in delisting.
- Geopolitical Risk: Operations are based in Israel. The ongoing conflict involving Hamas and regional instability poses risks to personnel availability, business continuity, and capital markets access.
- Clinical Trial Uncertainty: The company faces risks of failure in ongoing Phase III trials for Piclidenoson (psoriasis) and Namodenoson (HCC). Past trials in rheumatoid arthritis and dry-eye syndrome have failed to meet primary endpoints.
- Intellectual Property: The company no longer holds composition of matter patent exclusivity for Piclidenoson and Namodenoson due to the expiration of an NIH license in 2015, relying instead on data exclusivity and use patents.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $7.9 million cash balance against the projected burn rate, considering the contingency plan's impact on clinical trial timelines.
- Listing Compliance: Monitor the company's progress in regaining compliance with NYSE American shareholders' equity requirements to avoid delisting.
- Clinical Milestones: Track the initiation and progress of the pivotal Phase III study for Piclidenoson in psoriasis (initiated Q1 2025) and the Phase III LIVERATION study for Namodenoson in HCC.
- Capital Markets: Assess the impact of the ATM offering and warrant inducement transactions on shareholder dilution and future fundraising capacity.
- Geopolitical Exposure: Evaluate the potential for escalation in the Middle East to impact the company's small workforce (5 employees) and operational continuity in Israel.